FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3019661505> ?p ?o ?g. }

• W3019661505 abstract "Abstract Lysosomal diseases are a class of genetic disorders predominantly caused by loss of lysosomal hydrolases, leading to lysosomal and cellular dysfunction. Enzyme Replacement Therapy (ERT), where recombinant enzyme is given intravenously, internalized by cells, and trafficked to the lysosome, has been applied to treat several lysosomal diseases. However, current ERT regimens do not correct disease phenotypes in all affected organs because the biodistribution of enzyme uptake does not match that of the affected cells and tissues that require the enzyme. We present here targeted ERT, an approach that utilizes antibody-enzyme fusion proteins to target the enzyme to specific tissues. The antibody moiety recognizes transmembrane proteins involved in lysosomal trafficking and that are also preferentially expressed in those cells most affected in disease. Using Pompe disease (PD) as an example, we show that targeted ERT is superior to ERT in treating the skeletal muscle phenotypes of PD mice." @default.
• W3019661505 created "2020-05-01" @default.
• W3019661505 creator A5000989314 @default.
• W3019661505 creator A5002782925 @default.
• W3019661505 creator A5010490688 @default.
• W3019661505 creator A5023492006 @default.
• W3019661505 creator A5025553961 @default.
• W3019661505 creator A5031810848 @default.
• W3019661505 creator A5034785181 @default.
• W3019661505 creator A5036682345 @default.
• W3019661505 creator A5042428267 @default.
• W3019661505 creator A5043523035 @default.
• W3019661505 creator A5047258075 @default.
• W3019661505 creator A5058455741 @default.
• W3019661505 creator A5060015801 @default.
• W3019661505 creator A5061539926 @default.
• W3019661505 creator A5064638393 @default.
• W3019661505 creator A5067322377 @default.
• W3019661505 creator A5067609476 @default.
• W3019661505 creator A5069244564 @default.
• W3019661505 creator A5070429237 @default.
• W3019661505 creator A5075712626 @default.
• W3019661505 date "2020-04-23" @default.
• W3019661505 modified "2023-10-14" @default.
• W3019661505 title "Targeted delivery of acid alpha-glucosidase corrects skeletal muscle phenotypes in Pompe disease mice" @default.
• W3019661505 cites W1581834336 @default.
• W3019661505 cites W1965222084 @default.
• W3019661505 cites W1966752271 @default.
• W3019661505 cites W1969441539 @default.
• W3019661505 cites W1971439989 @default.
• W3019661505 cites W1972504196 @default.
• W3019661505 cites W1979002716 @default.
• W3019661505 cites W1986979860 @default.
• W3019661505 cites W2012034410 @default.
• W3019661505 cites W2014246297 @default.
• W3019661505 cites W2019926561 @default.
• W3019661505 cites W2026342372 @default.
• W3019661505 cites W2031724207 @default.
• W3019661505 cites W2036562453 @default.
• W3019661505 cites W2041769721 @default.
• W3019661505 cites W2045817726 @default.
• W3019661505 cites W2046115241 @default.
• W3019661505 cites W2048805044 @default.
• W3019661505 cites W2052344595 @default.
• W3019661505 cites W2057332675 @default.
• W3019661505 cites W2062886670 @default.
• W3019661505 cites W2082315344 @default.
• W3019661505 cites W2083805206 @default.
• W3019661505 cites W2084276666 @default.
• W3019661505 cites W2090407227 @default.
• W3019661505 cites W2097778362 @default.
• W3019661505 cites W2098331662 @default.
• W3019661505 cites W2127364492 @default.
• W3019661505 cites W2127608615 @default.
• W3019661505 cites W2130633620 @default.
• W3019661505 cites W2136000647 @default.
• W3019661505 cites W2140140261 @default.
• W3019661505 cites W2143096892 @default.
• W3019661505 cites W2143609092 @default.
• W3019661505 cites W2147798737 @default.
• W3019661505 cites W2574524657 @default.
• W3019661505 cites W2609426395 @default.
• W3019661505 cites W2753413345 @default.
• W3019661505 cites W2774819103 @default.
• W3019661505 cites W2891103837 @default.
• W3019661505 cites W2894600652 @default.
• W3019661505 doi "https://doi.org/10.1101/2020.04.22.051672" @default.
• W3019661505 hasPublicationYear "2020" @default.
• W3019661505 type Work @default.
• W3019661505 sameAs 3019661505 @default.
• W3019661505 citedByCount "1" @default.
• W3019661505 countsByYear W30196615052023 @default.
• W3019661505 crossrefType "posted-content" @default.
• W3019661505 hasAuthorship W3019661505A5000989314 @default.
• W3019661505 hasAuthorship W3019661505A5002782925 @default.
• W3019661505 hasAuthorship W3019661505A5010490688 @default.
• W3019661505 hasAuthorship W3019661505A5023492006 @default.
• W3019661505 hasAuthorship W3019661505A5025553961 @default.
• W3019661505 hasAuthorship W3019661505A5031810848 @default.
• W3019661505 hasAuthorship W3019661505A5034785181 @default.
• W3019661505 hasAuthorship W3019661505A5036682345 @default.
• W3019661505 hasAuthorship W3019661505A5042428267 @default.
• W3019661505 hasAuthorship W3019661505A5043523035 @default.
• W3019661505 hasAuthorship W3019661505A5047258075 @default.
• W3019661505 hasAuthorship W3019661505A5058455741 @default.
• W3019661505 hasAuthorship W3019661505A5060015801 @default.
• W3019661505 hasAuthorship W3019661505A5061539926 @default.
• W3019661505 hasAuthorship W3019661505A5064638393 @default.
• W3019661505 hasAuthorship W3019661505A5067322377 @default.
• W3019661505 hasAuthorship W3019661505A5067609476 @default.
• W3019661505 hasAuthorship W3019661505A5069244564 @default.
• W3019661505 hasAuthorship W3019661505A5070429237 @default.
• W3019661505 hasAuthorship W3019661505A5075712626 @default.
• W3019661505 hasBestOaLocation W30196615051 @default.
• W3019661505 hasConcept C104317684 @default.
• W3019661505 hasConcept C127716648 @default.
• W3019661505 hasConcept C142724271 @default.
• W3019661505 hasConcept C159654299 @default.
• W3019661505 hasConcept C170493617 @default.
• W3019661505 hasConcept C181199279 @default.

• next